ASH 2020 Updates in Non-CLL B-Cell Lymphomas

EP: 1.ASH 2020 Updates in CLL

Now Viewing

EP: 2.ASH 2020 Updates in Non-CLL B-Cell Lymphomas

EP: 3.ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas

Key opinion leaders provide insight into data updates from the ASH (American Society of Hematology) 2020 Annual Meeting on developments in agents for the management of non-CLL (chronic lymphocytic leukemia) B-cell lymphomas.

Data from the following clinical trials are discussed:

• Abstract 2109: Selinexor in Combination with R-CHOP for Front-Line Treatment of Non-Hodgkin Lymphoma: Results of a Phase 1b Study

• Abstract 405: Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)